PENTIDS '250'

Pre-Launch

penicillin g potassium

ANDAORALTABLET

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

PENTIDS '250' (penicillin g potassium) by Bristol Myers Squibb is clinical pharmacology after an intravenous infusion of penicillin g, peak serum concentrations are attained immediately after completion of the infusion. Approved for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below.

Drug data last refreshed 1mo ago

Mechanism of Action

CLINICAL PHARMACOLOGY After an intravenous infusion of penicillin G, peak serum concentrations are attained immediately after completion of the infusion. In a study of ten patients administered a single 5 million unit dose of penicillin G intravenously over 3 to 5 minutes, the mean serum…

Worked on PENTIDS '250' at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

PENTIDS '250'

Mechanism of Action

Indications (1)